Stephen Ryder

18.1k total citations · 3 hit papers
199 papers, 7.6k citations indexed

About

Stephen Ryder is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Stephen Ryder has authored 199 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Epidemiology, 112 papers in Hepatology and 34 papers in Surgery. Recurrent topics in Stephen Ryder's work include Liver Disease Diagnosis and Treatment (106 papers), Liver Disease and Transplantation (59 papers) and Hepatitis C virus research (49 papers). Stephen Ryder is often cited by papers focused on Liver Disease Diagnosis and Treatment (106 papers), Liver Disease and Transplantation (59 papers) and Hepatitis C virus research (49 papers). Stephen Ryder collaborates with scholars based in United Kingdom, United States and Canada. Stephen Ryder's co-authors include Guruprasad P. Aithal, Peter James, William Rosenberg, William L. Irving, S. A. C. Hawkins, Indra Neil Guha, Julie Parkes, Paul Roderick, Jonathan M. Rhodes and Adam Lawson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Stephen Ryder

194 papers receiving 7.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

2007 578 citations Indra Neil Guha, Paul Roderick et al. profile →
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

2008 545 citations Guruprasad P. Aithal, Stephen Ryder et al. profile →
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis

2021 194 citations Ewan Forrest, Stephen Ryder et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Stephen Ryder	4.3k	3.5k	1.9k	1.2k	848	199	7.6k
Javier Crespo	3.7k 0.9×	2.3k 0.7×	1.4k 0.8×	932 0.8×	669 0.8×	365	7.1k
Andrew D. Clouston	4.9k 1.1×	3.8k 1.1×	1.4k 0.7×	2.7k 2.2×	938 1.1×	197	11.4k
Luca Miele	4.4k 1.0×	1.5k 0.4×	1.8k 0.9×	961 0.8×	1.9k 2.2×	193	6.7k
Hans Van Vlierberghe	3.8k 0.9×	4.3k 1.2×	1.9k 1.0×	2.1k 1.8×	311 0.4×	332	8.6k
Takeshi Okanoue	8.7k 2.0×	6.2k 1.8×	3.9k 2.0×	2.3k 1.9×	2.6k 3.0×	390	15.5k
Elwyn Elias	3.6k 0.9×	4.6k 1.3×	937 0.5×	3.0k 2.5×	306 0.4×	229	8.5k
Wan‐Long Chuang	8.3k 2.0×	8.5k 2.4×	939 0.5×	732 0.6×	563 0.7×	513	11.1k
Masanori Abe	3.1k 0.7×	2.4k 0.7×	751 0.4×	995 0.8×	613 0.7×	307	6.3k
Jay H. Lefkowitch	4.9k 1.2×	4.4k 1.3×	1.6k 0.8×	1.4k 1.2×	523 0.6×	141	8.6k
Mario Pirisi	2.8k 0.7×	2.7k 0.8×	680 0.4×	678 0.6×	446 0.5×	308	6.1k

Countries citing papers authored by Stephen Ryder

Since Specialization

Citations

This map shows the geographic impact of Stephen Ryder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Ryder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Ryder more than expected).

Fields of papers citing papers by Stephen Ryder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Ryder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Ryder. The network helps show where Stephen Ryder may publish in the future.

Co-authorship network of co-authors of Stephen Ryder

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Ryder. A scholar is included among the top collaborators of Stephen Ryder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Ryder. Stephen Ryder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ryder, Stephen, et al.. (2025). P63 Bridging inequality through innovation: systems-based proactive approach to reduce asthma exacerbations in a novel nurse-led model in areas of social deprivation. A170.2–A171.

Khanna, Amardeep, et al.. (2024). Screening for Alcohol Use Disorder Among Hospitalised Patients: Learning from a Retrospective Cohort Study in Secondary Care. Journal of Clinical Medicine. 13(24). 7617–7617. 1 indexed citations

Jarvis, Helen, et al.. (2024). Increasing engagement with liver disease management across the UK: a follow-up cross-sectional survey. BJGP Open. 9(1). BJGPO.2024.0142–BJGPO.2024.0142. 1 indexed citations

MacDonald, Douglas, Paul Richardson, Stephen Ryder, et al.. (2023). Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International. 43(4). 917–927. 9 indexed citations

Rennick‐Egglestone, Stefan, Holly Knight, Katy A. Jones, et al.. (2023). Transient Elastography and Video Recovery Narrative Access to Support Recovery From Alcohol Misuse: Development of a Novel Intervention for Use in Community Alcohol Treatment Services. JMIR Formative Research. 7. e47109–e47109. 1 indexed citations

Knight, Holly, Joanne R Morling, Katy A. Jones, et al.. (2022). Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis. PLoS ONE. 17(5). e0268034–e0268034. 4 indexed citations

Aspinall, Richard, Mark Hudson, Stephen Ryder, et al.. (2022). Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II). Frontline Gastroenterology. 14(3). 228–235. 2 indexed citations

Mennini, Francesco Saverio, Andrea Marcellusi, Sarah Robbins Scott, et al.. (2021). The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. Liver International. 41(5). 934–948. 18 indexed citations

Ryder, Stephen, et al.. (2021). How to interpret and manage abnormal liver blood test results in older people. British Journal of Hospital Medicine. 82(8). 1–8. 3 indexed citations

10.

Hebditch, Vanessa, et al.. (2021). P028 Chronic liver disease, platelet transfusion & quality of life – a British liver trust patient-survey. A24.2–A24. 1 indexed citations

11.

Lim, Young‐Suk, Chun‐Yen Lin, Jeong Heo, et al.. (2021). IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2. A77.1–A77. 1 indexed citations

12.

Ankcorn, Michael, Bengü Said, Dilys Morgan, et al.. (2020). Persistent Hepatitis E virus infection across England and Wales 2009‐2017: Demography, virology and outcomes. Journal of Viral Hepatitis. 28(2). 420–430. 14 indexed citations

13.

Johnson, Philip J., Sarah Berhane, Alex J Walker, et al.. (2020). Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis. 28(1). 168–176. 7 indexed citations

14.

Forrest, Ewan, Rohit Sinha, Stephen R. Atkinson, et al.. (2019). Baseline neutrophil‐to‐lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Alimentary Pharmacology & Therapeutics. 50(4). 442–453. 48 indexed citations

15.

Chan, Henry Lik‐Yuen, Marı́a Buti, Robert Flisiak, et al.. (2018). IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). A97.1–A97. 2 indexed citations

16.

Miller, Michael H., Kosh Agarwal, Ashley Brown, et al.. (2014). Review article: 2014 UK consensus guidelines – hepatitis C management and direct‐acting anti‐viral therapy. Alimentary Pharmacology & Therapeutics. 39(12). 1363–1375. 31 indexed citations

17.

McLernon, David J., Peter T. Donnan, Frank Sullivan, et al.. (2014). Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. BMJ Open. 4(6). e004837–e004837. 25 indexed citations

18.

Donnan, Peter T., David J. McLernon, John Dillon, et al.. (2009). Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technology Assessment. 13(25). iii–iv, ix. 56 indexed citations

19.

Rizzi, P M, Stephen Ryder, John Ramage, et al.. (1994). Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.. PubMed. 26(6). 3568–9. 10 indexed citations

20.

Raouf, A, N. Parker, Stephen Ryder, et al.. (1991). Ion exchange chromatography of purified colonic mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect.. Gut. 32(10). 1139–1145. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact